Sugi Predict

Sugi Predict / Compounds / SCHEMBL9329656

SCHEMBL9329656

SCHEMBL9329656

Nc1nccc2[nH]c(=O)[nH]c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 9/20 0.36
▸ PDE3A Q14432 9/20 0.36
▸ AURKA O14965 1/20 0.34
▸ NOS3 P29474 2/20 0.33
▸ NOS2 P35228 2/20 0.33
▸ FYN P06241 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ GRIA1 P42261 1/20 0.33
▸ LIMK1 P53667 2/20 0.33
▸ BRD4 O60885 1/20 0.32
▸ CDK5 Q00535 2/20 0.32
▸ CDK5R1 Q15078 1/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ CHEK1 O14757 1/20 0.32
▸ PRKD3 O94806 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ CDK1 P06493 1/20 0.32
▸ LYN P07948 1/20 0.32
▸ RET P07949 1/20 0.32
▸ PIM1 P11309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22621675 0.76 PDE3B (0.36) PDE3BPDE3AAURKAFYNMAPT
SCHEMBL259548 0.76 RXFP1 (0.46) PDE3BPDE3AAURKAGRIA1AURKB
SCHEMBL9329498 0.76 PDE3B (0.50) PDE3BPDE3AMAPTBRD4CDK5
SCHEMBL18237425 0.73 PDE3B (0.40) PDE3BPDE3AAURKAFYNLIMK1
SCHEMBL24835675 0.72 PDE3B (0.54) PDE3BPDE3ABRD4
SCHEMBL17867338 0.72 PDE3B (0.57) PDE3BPDE3AMAPTBRD4
SCHEMBL259866 0.71 MAPT (0.53) MAPT
SCHEMBL9332323 0.69 PDE3B (0.44) PDE3BPDE3A
SCHEMBL21895410 0.68 AURKA (0.45) AURKAMAPTBRD4
SCHEMBL2483323 0.67 POLB (0.52) PDE3BPDE3AAURKAMAPTGRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3603619-B1 VACCINE ADJUVANT FORMULATION SUMITOMO PHARMA CO LTD (JP) 2025-08-13 — — EP disclosed
US-20250009869-A1 COMPOSITION CONTAINING INFLUENZA VACCINE JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NAT INSTITUTE OF INFECTIOUS DISEASES (JP) 2025-01-09 — — US disclosed
CN-110650729-B Vaccine adjuvant formulations 住友制药株式会社 2024-08-20 — — CN disclosed
US-12059462-B2 Composition containing influenza vaccine JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) 2024-08-13 — — US disclosed
EP-3854799-B1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2024-07-17 — — EP disclosed
US-11833247-B2 Vaccine adjuvant formulation Sumitomo Pharma Co., Ltd. (JP) 2023-12-05 — — US disclosed
US-20220273563-A1 VACCINE ADJUVANT FORMULATION Sumitomo Pharma Co., Ltd. (JP) 2022-09-01 — — US disclosed
US-11253476-B2 Vaccine adjuvant formulation SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-02-22 — — US disclosed
US-20210353737-A1 COMPOSITION CONTAINING INFLUENZA VACCINE Sumitomo Pharma Co., Ltd. (JP) 2021-11-18 — — US disclosed
EP-3854799-A1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION Shanghai de Novo Pharmatech Co., Ltd. (CN) 2021-07-28 — — EP disclosed
EP-3827842-A1 COMPOSITION CONTAINING INFLUENZA VACCINE JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases (JP) 2021-06-02 — — EP disclosed
CN-112839673-A Compositions comprising influenza vaccines 日本国立感染症研究所所长代表之日本国 2021-05-25 — — CN disclosed
US-20200121600-A1 VACCINE ADJUVANT FORMULATION Sumitomo Pharma Co., Ltd. (JP) 2020-04-23 — — US disclosed
WO-2020057546-A1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION 上海迪诺医药科技有限公司 2020-03-26 — — WO disclosed
EP-3603619-A1 VACCINE ADJUVANT FORMULATION Sumitomo Dainippon Pharma Co., Ltd. (JP) 2020-02-05 — — EP disclosed
CN-110650729-A Vaccine adjuvant formulations 大日本住友制药株式会社 2020-01-03 — — CN disclosed
EP-0589914-A1 NOVEL 3-FUSED PYRIDINIUMMETHYL CEPHALOSPORINS CHEIL FOODS & CHEMICALS, INC. (KR) 1994-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833247-B2 Vaccine adjuvant formulation TLR7, TLR9, TLR5 PDE3B 3301/4885PDE3A 3751/4885AURKA 2188/4885
US-20220273563-A1 VACCINE ADJUVANT FORMULATION TLR7, TLR9, TLR5 PDE3B 3301/4885PDE3A 3751/4885AURKA 2188/4885
US-12059462-B2 Composition containing influenza vaccine LY96, CD209, PLA2G12B PDE3B 1499/4885PDE3A 1952/4885AURKA 2712/4885
US-11253476-B2 Vaccine adjuvant formulation TLR7, TLR9, TLR5 PDE3B 3301/4885PDE3A 3751/4885AURKA 2188/4885
US-20200121600-A1 VACCINE ADJUVANT FORMULATION TLR7, TLR9, TLR5 PDE3B 3301/4885PDE3A 3751/4885AURKA 2188/4885
US-20250009869-A1 COMPOSITION CONTAINING INFLUENZA VACCINE LY96, CD209, PLA2G12B PDE3B 1499/4885PDE3A 1952/4885AURKA 2712/4885
US-20210353737-A1 COMPOSITION CONTAINING INFLUENZA VACCINE LY96, CD209, PLA2G12B PDE3B 1499/4885PDE3A 1952/4885AURKA 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.